Table 3 Lifetime Expected Outcomes among Survivors to Discharge
By BPD Severity | By Gestational Age at Birth | ||||||
|---|---|---|---|---|---|---|---|
Total | No/Low BPD | Intermediate | Severe | 27–28 | 25–26 | < 25 | |
Expected Lifetime Outcomes (95% CI rounded to nearest 1000) | |||||||
Costs | $ 716,912 (416,000 – 1,275,000) | $ 554,650 (298,000 – 960,000) | $ 865,550 (285,000 – 1,471,000) | $ 938,900 (550,000 – 1,748,000) | $ 657,994 (376,000 – 1000,000) | $ 708,416 (419,000 – 1,117,000) | $ 749,110 (531,000 – 1,379,000) |
QALYs | 42.1 (37.2–48.1) | 50.4 (45.1–55.8) | 33.2 (29.3–39.1) | 20.1 (16.0–22.5) | 43.8 (34.9–48.1) | 40.6 (34.7–46.4) | 37.4 (31.1–41.1) |
Expected Complication Prevalence | |||||||
Neuro-Impairment | 47% | 34% | 59% | 79% | 45% | 49% | 53% |
ADHD | 8% | 9% | 6% | 6% | 8% | 8% | 7% |
Neuro-Development Delay | 18% | 14% | 24% | 22% | 17% | 18% | 19% |
Asthma | 36% | 36% | 36% | 34% | 35% | 36% | 36% |
Hearing Impairment | 9% | 6% | 15% | 10% | 8% | 9% | 10% |
Retinopathy | 14% | 9% | 21% | 21% | 13% | 15% | 16% |
Pulmonary Hypertension | 2% | 0% | 4% | 7% | 2% | 2% | 3% |